Abstract
Curcumin, a polyphenol isolated from the plant Curcuma longa, displays chemotherapeutic and chemopreventive effects in diverse cancers, including colorectal cancer. A mono-carbonyl analogue B63 was synthesized through several chemical modifications of the basic structure of curcumin to increase its biological activity and bioavailability. In vitro assays showed potent anti-proliferative effects of B63 on colon cancer cells (about 2 fold more effective than curcumin based on IC50). B63 treatment also induced significant necrosis, apoptosis, and S phase cell cycle arrest in SW620 colon cancer cells. The pro-apoptotic proteins Bad and Bim were up-regulated, and cytochrome c release from the mitochondria into the cytosol was enhanced, resulting in pro-caspase-3 and PARP-1 cleavage. Furthermore, the anticancer activity of B63 was dependent on intracellular ROS from damaged mitochondrial function and induced endoplasmic reticulum (ER) stress. In vivo, 50 mg/kg of B63 inhibit tumor growth similarly to 100 mg/kg curcumin in a mouse xenograft model using SW620 cells. These results suggest that the curcumin derivative B63 has a greater anticancer capacity than the parent curcumin in colon cancer cells and that the necrotic and apoptotic effects of B63 are mediated by ROS resulting from ER stress and mitochondrial dysfunction.
Keywords: Colon cancer cells, curcumin, curcumin derivative, ER stress, mitochondrial dysfunction, ROS.
Current Cancer Drug Targets
Title:Anticancer Effect of a Curcumin Derivative B63: ROS Production and Mitochondrial Dysfunction
Volume: 14 Issue: 2
Author(s): Adi Zheng, Hao Li, Xun Wang, Zhihui Feng, Jie Xu, Ke Cao, Bo Zhou, Jing Wu and Jiankang Liu
Affiliation:
Keywords: Colon cancer cells, curcumin, curcumin derivative, ER stress, mitochondrial dysfunction, ROS.
Abstract: Curcumin, a polyphenol isolated from the plant Curcuma longa, displays chemotherapeutic and chemopreventive effects in diverse cancers, including colorectal cancer. A mono-carbonyl analogue B63 was synthesized through several chemical modifications of the basic structure of curcumin to increase its biological activity and bioavailability. In vitro assays showed potent anti-proliferative effects of B63 on colon cancer cells (about 2 fold more effective than curcumin based on IC50). B63 treatment also induced significant necrosis, apoptosis, and S phase cell cycle arrest in SW620 colon cancer cells. The pro-apoptotic proteins Bad and Bim were up-regulated, and cytochrome c release from the mitochondria into the cytosol was enhanced, resulting in pro-caspase-3 and PARP-1 cleavage. Furthermore, the anticancer activity of B63 was dependent on intracellular ROS from damaged mitochondrial function and induced endoplasmic reticulum (ER) stress. In vivo, 50 mg/kg of B63 inhibit tumor growth similarly to 100 mg/kg curcumin in a mouse xenograft model using SW620 cells. These results suggest that the curcumin derivative B63 has a greater anticancer capacity than the parent curcumin in colon cancer cells and that the necrotic and apoptotic effects of B63 are mediated by ROS resulting from ER stress and mitochondrial dysfunction.
Export Options
About this article
Cite this article as:
Zheng Adi, Li Hao, Wang Xun, Feng Zhihui, Xu Jie, Cao Ke, Zhou Bo, Wu Jing and Liu Jiankang, Anticancer Effect of a Curcumin Derivative B63: ROS Production and Mitochondrial Dysfunction, Current Cancer Drug Targets 2014; 14 (2) . https://dx.doi.org/10.2174/1568009613666131126115444
DOI https://dx.doi.org/10.2174/1568009613666131126115444 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transmembrane Protein 166 and its Significance
Protein & Peptide Letters Genitourinary Tract Tumors in Children: An Update
Current Pediatric Reviews Indolic Structure Metabolites as Potential Biomarkers of Non-infectious Diseases
Current Pharmaceutical Design HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Emergence of Functionalized Nanomedicines in Cancer Chemotherapy: Recent Advancements, Current Challenges and Toxicity Considerations
Recent Patents on Nanomedicine Elucidation of PLK1 Linked Biomarkers in Oesophageal Cancer Cell Lines: A Step Towards Novel Signaling Pathways by p53 and PLK1-Linked Functions Crosstalk
Protein & Peptide Letters Inhibition of Topoisomerase I by Anti-Cancer Drug Altered the Endometrial Cyclicity and Receptivity
Current Molecular Medicine 4-Hydroxynonenal in the Pathogenesis and Progression of Human Diseases
Current Medicinal Chemistry Quantitative Structure-Activity Relationships for Anticancer Activity of 2- Phenylindoles Using Mathematical Molecular Descriptors
Current Computer-Aided Drug Design Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
Current Cancer Drug Targets Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Current Molecular Medicine Mitochondria: A Promising Target for Anticancer Alkaloids
Current Topics in Medicinal Chemistry Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer
Current Gene Therapy Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis
Current Cancer Drug Targets Editorial [Hot topic: Angiogenesis and Lymphangiogenesis in Common Diseases (Guest Editor: Y. Cao)]
Current Molecular Medicine Nucleoprotein-Derived and Unbound Ribonucleosides: Bioactivity and Potential Applications
Current Pharmaceutical Design Chemoradiotherapy in Rectal Cancer
Current Drug Therapy Diastereoselective Addition of Organometallic Reagents to Diimines Derived from (R,R)-1,2-Diaminocyclohexane and Aromatic Aldehydes
Letters in Organic Chemistry Ceramide-Based Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry